Raymond James & Associates Chemo Centryx, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

Shares

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Oct 25, 2022	SELL	$22.17 - $51.8 $5.38 Million - $12.6 Million	-242,552 Reduced 85.52%	41,068 $2.12 Million
Q2 2022 Aug 12, 2022	SELL	$15.36 - $27.51 $172,231 - $308,469	-11,213 Reduced 3.8%	283,620 $7.03 Million
Q1 2022 May 11, 2022	BUY	$22.22 - $39.12 $377,628 - $664,844	16,995 Added 6.12%	294,833 $7.39 Million
Q4 2021 Feb 08, 2022	SELL	$18.38 - $40.5 $1.42 Million - $3.13 Million	-77,352 Reduced 21.78%	277,838 $10.1 Million
Q3 2021 Nov 02, 2021	BUY	$13.18 - $19.83 $64,634 - $97,246	4,904 Added 1.4%	355,190 $6.07 Million
Q2 2021 Aug 11, 2021	BUY	$9.59 - $50.88 $792,891 - $4.21 Million	82,679 Added 30.9%	350,286 $4.69 Million
Q1 2021 May 14, 2021	BUY	$49.53 - $68.4 $1.94 Million - $2.68 Million	39,204 Added 17.16%	267,607 $13.7 Million
Q4 2020 Feb 12, 2021	BUY	$47.25 - $65.16 $6.92 Million - $9.55 Million	146,524 Added 178.95%	228,403 $14.1 Million
Q3 2020 Nov 04, 2020	BUY	$46.35 - $61.69 $845,516 - $1.13 Million	18,242 Added 28.67%	81,879 $4.49 Million
Q2 2020 Jul 28, 2020	BUY	$38.58 - $65.07 $255,939 - $431,674	6,634 Added 11.64%	63,637 $3.66 Million
Q1 2020 Apr 21, 2020	BUY	$32.73 - $50.78 $850,619 - $1.32 Million	25,989 Added 83.8%	57,003 $2.29 Million
Q4 2019 Feb 12, 2020	BUY	$6.81 - $39.55 $76,592 - $444,818	11,247 Added 56.9%	31,014 $1.23 Million
Q3 2019 Nov 07, 2019	BUY	$6.47 - $8.96 $31,981 - $44,289	4,943 Added 33.34%	19,767 $134,000
Q2 2019 Aug 06, 2019	BUY	$8.31 - $14.85 $7,894 - $14,107	950 Added 6.85%	14,824 $138,000
Q1 2019 May 06, 2019	BUY	$10.01 - $13.89 $17,017 - $23,613	1,700 Added 13.96%	13,874 $193,000
Q4 2018 Feb 11, 2019	BUY	$9.15 - $12.26 $111,392 - $149,253	12,174 New	12,174 $133,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.